Andrew Krivoshik, M.D., Ph.D. (PD ’02), chief medical officer, Frontier Medicines

Andrew Krivoshik, M.D., Ph.D. (PD ’02), is chief medical officer at Frontier Medicines, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets. Dr. Krivoshik brings two decades of experience in global clinical development, biomarker strategy, translational medicine, product and patient safety, and medical affairs. Prior to this, Dr. Krivoshik was president and head of development at Astellas, where he managed global clinical development activities and global functions.